Full-Time

Data Platform Runops Engineer

Posted on 11/23/2025

Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

No salary listed

Hyderabad, Telangana, India

In Person

Must work during US business hours

Category
Data & Analytics (1)
Required Skills
Kubernetes
Agile
Python
NoSQL
Data Science
Git
SQL
Java
Microservices
AWS
JIRA
DevOps
Databricks
Requirements
  • Master's degree or Bachelor's degree and 5 to 9 years of relevant experience.
  • Experience with Databricks capabilities including but not limited to setting up AI capabilities, cluster setup, execution, and tuning.
  • Experience with AWS services including but not limited to MSK, IAM, EC2, EKS and S3.
  • Experience with data lake, data fabric and data mesh concepts.
  • Experience with platform performance optimization.
  • Experience working with relational databases.
  • Experience building ETL or ELT pipelines; Hands-on experience with SQL/NoSQL.
  • Knowledge of distributed systems and microservices.
  • Proficiency in one or more programming languages such as SQL, Python, or Java.
  • Experience with software engineering best-practices, including version control (Git, GitLab), CI/CD (GitLab or similar), automated unit testing, and DevOps.
  • Exposure to Jira or Jira Align.
  • Skills needed to assist business users.
  • Excellent analytical and problem-solving skills.
  • Excellent written and verbal communications skills (English) in translating technology content into business-language at various levels.
  • Ability to work effectively with global, virtual teams.
  • High degree of initiative and self-motivation.
  • Ability to manage multiple priorities successfully.
  • Team-oriented, with a focus on achieving team goals.
  • Strong problem-solving and analytical skills.
  • Strong time and task leadership skills to estimate and successfully meet project timeline with ability to bring consistency and quality assurance across various projects.
Responsibilities
  • Work closely with the Enterprise Data Lake delivery and platform teams to ensure that the applications are aligned with the overall architectural and development guidelines.
  • Research and evaluate technical solutions including Databricks, AWS Services, Kubernetes/EKS, NoSQL databases, Data Science packages, platforms and tools with a focus on enterprise deployment capabilities like security, scalability, reliability, maintainability, cost management etc.
  • Management of Enterprise Data Lake/Fabric platform incidents related to Databricks, AWS Services, Kubernetes/EKS, NoSQL databases, platforms and tools.
  • Assist in building and managing relationships with internal and external business stakeholders.
  • Develop basic understanding of core business problems and identify opportunities to use advanced analytics.
  • Work closely with the Enterprise Data Lake ecosystem leads to identify and evaluate emerging providers of data management & processing components that could be incorporated into data platform.
  • Work with platform stakeholders to ensure effective cost observability and control mechanisms are in place for all aspects of data platform management.
  • Experience working in Agile environments and participating in Agile ceremonies.
  • Keen on adopting new responsibilities, facing challenges, and mastering new technologies.
  • Work during US business hours to support cross-functional teams including Manufacturing, Commercial, and Research & Development in their use of Enterprise Data Lake.
Desired Qualifications
  • Experience in Cloud technologies AWS preferred.
  • Cloud Certifications -AWS, Databricks, Microsoft
  • Familiarity with the use of AI for development productivity, such as GitHub Copilot, Databricks Assistant, Amazon Q Developer or equivalent.
  • Knowledge of Agile and DevOps practices.
  • Skills in disaster recovery planning.
  • Familiarity with load testing tools (JMeter, Gatling).
  • Basic understanding of AI/ML for monitoring.
  • Data visualization skills (Tableau, Power BI).
  • Strong communication and leadership skills.
  • Understanding of compliance and auditing requirements.
  • Knowledge of Low code/No Code platform like Prophecy
  • Familiarity with Shell Scripting
  • Working knowledge with ServiceNow.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Tarlatamab wins China NMPA approval May 2026 for $2B+ sales potential.
  • Q1 2026 revenues hit $8.6B with 16 brands posting double-digit growth.
  • Zai Lab partners on DLL3-ADC plus IMDELLTRA for SCLC trials.

What critics are saying

  • Prolia sales drop 34% to $727M from biosimilar competition in Q1 2026.
  • FDA warns Tavneos causes liver injuries, proposes approval withdrawal.
  • Horizon drugs Tepezza, Uplizna, Krystexxa underperform 19 months post-acquisition.

What makes Amgen unique

  • Amgen's BiTE platform establishes IMDELLTRA as second-line SCLC standard.
  • MariTide advances in Phase III obesity trials with monthly dosing.
  • UPLIZNA surges 73% post-IgG4 and gMG approvals in 2025.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Apr 3rd, 2026
Amgen faces Tavneos liver injury warning as Zai Lab oncology collaboration expands IMDELLTRA pipeline

Amgen faces fresh safety concerns after the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Tavneos (avacopan) in late March 2026. The development adds regulatory risk to the company's investment profile. Separately, Zai Lab announced a global collaboration with Amgen to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer, underscoring the company's ongoing oncology expansion through external partnerships. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. However, pessimistic analysts model revenues slipping to $34.4 billion with earnings near $5.2 billion, reflecting concerns around pricing pressure, biosimilar competition and rising research and development spend alongside the new safety issues.

Yahoo Finance
Mar 30th, 2026
Amgen stock up 24% since Jim Cramer's June recommendation, beats earnings estimates

Amgen, one of the world's largest pharmaceutical companies, has seen its shares rise 24% since Jim Cramer discussed the stock on Mad Money in June 2025. The company is currently developing the weight loss drug MariTide. Amgen's shares jumped 7.5% in November 2025 after posting third-quarter results that beat analyst expectations, with $9.6 billion in revenue and $5.64 earnings per share against forecasts of $8.98 billion and $5.04 respectively. In February 2026, shares rose 8% following fourth-quarter earnings that also exceeded estimates. Cramer expressed cautious optimism about the biotech company, noting its mid-single-digit earnings growth and potential upside from its GLP-1 drug development. Whilst calling Eli Lilly his preferred GLP-1 play, Cramer said investors "could do a lot worse than Amgen" for a bargain option.

Yahoo Finance
Mar 25th, 2026
Wells Fargo lifts Amgen price target to $390, cites $20B myasthenia gravis market potential by 2036

Wells Fargo has raised its price target on Amgen to $390 from $375, maintaining an Equal Weight rating. The firm cited emerging therapies including CD20, BAFF/APRIL and next-generation complement inhibitors as potential drivers that could expand the generalized myasthenia gravis market threefold over the next decade, potentially reaching $15 billion in US sales and $20 billion globally by 2036. Separately, Jefferies initiated coverage on Amgen with a Hold rating and $350 price target on 10 March, noting the stock has gained approximately 35% over the past six months. Last month, Amgen reported fourth-quarter adjusted earnings per share of $5.29, beating the $4.76 consensus estimate, on revenue of $9.9 billion versus $9.45 billion expected.

Yahoo Finance
Mar 15th, 2026
Amgen joins TrumpRx discount scheme and lifts dividend to $2.52 per share

Amgen has announced a $2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs including Amjevita, Aimovig and Repatha. The company is also preparing for its 11 March presentation at the Leerink Global Healthcare Conference in Miami. The moves come alongside double-digit revenue and earnings per share growth in 2025 and advances in obesity and oncology programmes. However, the TrumpRx discounting could pressure net pricing as Amgen invests heavily in late-stage trials and manufacturing expansion. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. Some analysts see a tougher outlook, with revenue potentially drifting towards $34.4 billion and earnings around $5.2 billion.

INACTIVE